Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scorpion Therapeutics IncfiledCriticalScorpion Therapeutics Inc
Publication of AR123576A1publicationCriticalpatent/AR123576A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente divulgación proporciona entidades químicas (p. ej., un compuesto o una sal farmacéuticamente aceptable, y/o un hidrato, y/o un cocristal, y/o una combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor del factor de crecimiento epidérmico humano 2 (HER2, ERBB2). Estas entidades químicas son útiles, p. ej., para tratar una afección, enfermedad o trastorno en el que el aumento (p. ej., excesivo) de la activación del EGFR y/o del HER2 contribuye a la patología y/o a los síntomas y/o a la progresión de la afección, enfermedad o trastorno (p. ej., cáncer) en un sujeto (p. ej., un humano). La presente divulgación también proporciona composiciones que las contienen, así como métodos de uso y fabricación de estas.The present disclosure provides chemical entities (eg, a compound or a pharmaceutically acceptable salt, and/or a hydrate, and/or a co-crystal, and/or a drug combination of the compound) that inhibit the growth factor receptor. epidermal (EGFR, ERBB1) and/or human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g. to treat a condition, disease, or disorder in which increased (eg, excessive) activation of EGFR and/or HER2 contributes to the pathology and/or symptoms and/or progression of the disease condition, disease or disorder (eg, cancer) in a subject (eg, a human). The present disclosure also provides compositions containing them, as well as methods of using and manufacturing them.
ARP210102635A2020-09-232021-09-23
METHODS TO TREAT CANCER
AR123576A1
(en)
Dosage form comprising the compound (s) -3- (4 - ((4-morpholinomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidin-2,6-dione, an amount of 90 to 99, 9 percent by weight of the total weight of a mixture of starch and lactose as carrier or excipient, and stearic acid as a lubricant; its use in the treatment of cancer and autoimmune diseases, among others.